What the FDA decided on Gazyva for Idiopathic nephrotic syndrome
The FDA approved Gazyva (obinutuzumab) for idiopathic nephrotic syndrome.
Approved September 25, 2026 to reduce the risk of relapse in adults and children 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. Idiopathic nephrotic syndrome is the most common cause of nephrotic syndrome in children, usually starting between ages 2 and 7.
In the 85-patient Phase 3 INShore trial (NCT05627557), significantly more patients on Gazyva stayed relapse-free with normal urine protein at week 52 than on mycophenolate mofetil, a common standard treatment. Gazyva was already approved for certain blood cancers and for lupus nephritis. The label carries a boxed warning for hepatitis B reactivation and progressive multifocal leukoencephalopathy, a rare brain infection; the most common side effects in this use were infections, infusion reactions and low neutrophil counts. It held Breakthrough Therapy, Orphan Drug and Priority Review designations.
How Gazyva works
Gazyva: anti-CD20 antibody that removes B cells. Our full Gazyva profile covers how it works, side effects in plain language, and its trial history.
Frequently asked questions
Has the FDA decided on Gazyva?
The FDA has already decided. It approved the application.
Details: the outcome and what it means are at the top of this page.
Source: FDA approval notice
What was Gazyva approved for?
The FDA approved Genentech (Roche)'s sBLA for Gazyva in Idiopathic nephrotic syndrome.
What to know: Approved September 25, 2026 to reduce the risk of relapse in adults and children 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. Idiopathic nephrotic syndrome is the most common cause of nephrotic syndrome in children, usually starting between ages 2 and 7. In the 85-patient Phase 3 INShore trial (NCT05627557), significantly more patients on Gazyva stayed relapse-free with normal urine protein at week 52 than on mycophenolate mofetil, a common standard treatment. Gazyva was already approved for certain blood cancers and for lupus nephritis. The label carries a boxed warning for hepatitis B reactivation and progressive multifocal leukoencephalopathy, a rare brain infection; the most common side effects in this use were infections, infusion reactions and low neutrophil counts. It held Breakthrough Therapy, Orphan Drug and Priority Review designations.
How it works: Anti-CD20 antibody that removes B cells.
More: the Gazyva drug page explains it in plain language.
What did the Gazyva trials show?
In REGENCY (NCT04221477), 271 adults with lupus nephritis added Gazyva or placebo to standard therapy. At week 76, 46.4% on Gazyva had a complete kidney response against 33.1% on placebo.
More: the Gazyva drug page has the full trial history and sources.
What are the side effects of Gazyva?
Gazyva has a boxed warning for hepatitis B coming back and for PML, a rare, serious brain infection. In the pooled lupus nephritis trials, the most common side effects against placebo were upper respiratory infections (29% against 24%), COVID-19 (23% against 16%), urinary tract infections (21% against 18%), bronchitis (14% against 8%), infusion reactions (14% against 10%), low white blood cell counts (14% against 6%) and pneumonia (10% against 6%).
More: the Gazyva drug page has the label's warnings in full.
How much will Gazyva cost?
Trial Friend does not list a price for Gazyva. What you pay depends on your insurance and on help from the drugmaker or a charity fund.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Gazyva decision?
The FDA approved Gazyva for Idiopathic nephrotic syndrome on September 25, 2026.
Next steps: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
Where this outcome comes from
The outcome on this page comes from FDA approval notice. This page rechecks against our calendar, which is re-verified daily.